Resource Centers
Spotlight
Business
News
Conferences
Partners
CME/CE
Subscribe
- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Examining Health Equity Among Different Racial and Ethnic Subpopulations With Multiple Sclerosis : Episode 5
Challenges to Equal Access in MS Treatment
The Medicaid group exhibited higher rates of MS-related complications than did the commercial group, such as gait abnormalities (17.3% vs 10.4%); burning, numbness or tingling (21.9% vs 17.9%); dizziness/vertigo (14.6% vs 9.2%); and urinary incontinence (16.0% vs 5.8%; P < .001 for all). The Medicaid group also had a higher rate with nearly all comorbidities, such as hypertension (35.7% vs 30.2%), diabetes (16.6% vs 9.6%) and asthma (15.9% vs 6.0%; P < .001 for all). (19)
Related Videos
